The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The initial report of RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery.
Mohan Suntharalingam
No relevant relationships to disclose
Kathryn Winter
No relevant relationships to disclose
David H. Ilson
No relevant relationships to disclose
Adam Dicker
No relevant relationships to disclose
Lisa A. Kachnic
No relevant relationships to disclose
Andre A. Konski
No relevant relationships to disclose
Bapsi Chakravarthy
No relevant relationships to disclose
David K. Gaffney
No relevant relationships to disclose
Harish V. Thakrar
No relevant relationships to disclose
Margit Naomi Horiba
No relevant relationships to disclose
Melvin Deutsch
No relevant relationships to disclose
Vivek Kavadi
No relevant relationships to disclose
Adam Raben
No relevant relationships to disclose
Kevin S. Roof
No relevant relationships to disclose
Gregory M. M. Videtic
No relevant relationships to disclose
Jondavid Pollock
No relevant relationships to disclose
Howard Safran
Disclosure not yet available
Christopher H. Crane
No relevant relationships to disclose